Talk:1-Amino-5-phosphonoindan-1-carboxylic acid

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about 1-Amino-5-phosphonoindan-1-carboxylic acid.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

On 25 December 2023, it was proposed that this article be moved to APICA (metabotropic glutamate receptor antagonist). The result of the discussion was Moved to 1-Amino-5-phosphonoindan-1-carboxylic acid.

Requested move 25 December 2023[edit]

The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: Moved to 1-Amino-5-phosphonoindan-1-carboxylic acid. Consensus on the alternative. – robertsky (talk) 00:10, 11 January 2024 (UTC)[reply]

APICA (drug) → APICA (metabotropic glutamate receptor antagonist) – The current title is ambiguous with APICA (synthetic cannabinoid drug), and the other one attracts around 7× the pageviews. —⁠ ⁠BarrelProof (talk) 03:32, 25 December 2023 (UTC) — Relisting. – robertsky (talk) 17:37, 2 January 2024 (UTC)[reply]

Comment does the DAB tag need to be that long? Would prefer a shorter one, ~~but if not, would still support the proposed~~. Dank Jae 02:01, 29 December 2023 (UTC)[reply]

I considered APICA (receptor antagonist), but both topics seem to fit that description. How about 1-Amino-5-phosphonoindan-1-carboxylic acid? —⁠ ⁠BarrelProof (talk) 03:03, 29 December 2023 (UTC)[reply]

I guess best to do the full name, 1-Amino-5-phosphonoindan-1-carboxylic acid, as 2-Methyl-6-(phenylethynyl)pyridine a similar one uses the full name because MPEP isn't primarily used for it nor links to it. But maybe still make the initial proposed title a redirect. Ofc, should APICA be more used for this one, then that could be considered in the future. Dank Jae 20:28, 4 January 2024 (UTC)[reply]

Relisting comment: on the alternatives? – robertsky (talk) 17:37, 2 January 2024 (UTC)[reply]

Clarify, Move to 1-Amino-5-phosphonoindan-1-carboxylic acid. Dank Jae 04:05, 9 January 2024 (UTC)[reply]

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.